YR 001
Alternative Names: YR-001Latest Information Update: 19 Jul 2024
At a glance
- Originator YIRUI Pharmaceutical Technology
- Class Anti-inflammatories; Antipsoriatics; Skin disorder therapies; Small molecules
- Mechanism of Action Ion channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis
- Phase I Psoriasis
Most Recent Events
- 19 Jun 2024 Phase-II clinical trials in Atopic dermatitis in USA (Topical) (NCT06309355)
- 15 Mar 2024 Yirui Pharmaceutical Technology plans a phase II trial for Atopic dermatitis in USA (Topical) in June 2024 (NCT06309355)
- 14 Dec 2023 Hangzhou Yirui Pharmaceutical Technology completes a phase-I trial in Psoriasis and Atopic dermatitis (In adults, In the elderly, In volunteers) in USA (Topical, Ointment) (NCT05718921)